Cancer Vaccines
Immune Response Produced in Multiple Myeloma Patients
Published in Vaccine Weekly, August 11th, 1997
The vaccine was developed by Genzyme Transgenics Corp., Framingham, Massachusetts. The clinical trial was conducted by researchers at the U.S. National Cancer Institute (NCI) and University of Arkansas for Medical Sciences (UAMS).
The tumor-specific response experienced by patients in the trial indicates the vaccine's potential ability to reduce or eliminate residual cancer in patients who have not responded to other therapies. Based on these preliminary results, the company will accelerate vaccine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1997-08-11)
More Articles from Vaccine Weekly
- Cancer Immunology
Trouble for Cancer Vaccines: Tumors Don't Attract T Cells - AIDS Surveillance
First U.S. HIV-1 Subtype G, Second Group O Identified - AIDS Therapies
New Drug/Vaccine Targets: HIV NC Needed To Make Viral DNA - AIDS Vaccines
Better Understanding of gp120 Immunity Seen as Key to HIV Vaccine - Anthrax
Last State-Owned Vaccine Lab and Sole Producer of Anthrax Vaccine is For Sale - Cancer Vaccines
Payment Received for Achievement of BEC2 Vaccine Manufacturing - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
